Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)
Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a painful, dose-limiting adverse effect of commonly used chemotherapeutic agents. The purpose of this exploratory study was to evaluate the efficacy and safety of mirogabalin in patients with moderate to severe CIPN during chem...
Main Authors: | Sonoko Misawa, Tadamichi Denda, Sho Kodama, Takuji Suzuki, Yoichi Naito, Takahiro Kogawa, Mamoru Takada, Tomoki Suichi, Kazuhito Shiosakai, Satoshi Kuwabara, on behalf of the MiroCIP study group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-11560-4 |
Similar Items
-
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
by: Mitsuru Sugimoto, et al.
Published: (2021-12-01) -
Mirogabalin - the use of a new gabapentinoid in the treatment of diabetic neuropathy and postherpetic neuropathy and other conditions
by: Weronika Gawel, et al.
Published: (2023-01-01) -
Mirogabalin and emerging therapies for diabetic neuropathy
by: Javed S, et al.
Published: (2018-08-01) -
Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
by: Tomoko Tetsunaga, et al.
Published: (2020-05-01) -
Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
by: Masayuki Baba, et al.
Published: (2020-05-01)